Drugs · acquisition-cost intelligence
telmisartan and amlodipine
· ingredient amlodipineAngiotensin II receptor blockers (ARBs), plain· AMLODIPINE BESYLATE 10 mg/1; TELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; TELMISARTAN 80 mg/1; AMLODIPINE BESYLATE 5 mg/1; TELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; TELMISARTAN 80 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$2.85
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other amlodipine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| AMLODIPINE BESYLATE 10 mg | $0.01136 | −$2.83 |
| AMLODIPINE BESYLATE 10 mg | $0.01545 | −$2.83 |
| Lotrel | $0.11766 | −$2.73 |
| Amlodipine and Benazepril Hydrochloride | $0.14444 | −$2.70 |
| Amlodipine and Olmesartan Medoxomil | $0.29530 | −$2.55 |
| Exforge | $0.48831 | −$2.36 |
| OLMESARTAN MEDOXOMIL, AMLODIPINE and HYDROCHLOROTHIAZIDE | $1.23 | −$1.62 |
| Caduet | $1.41 | −$1.43 |
Medicare Part D coverage · CY2026
On 165 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 59% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.